Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 8
Submit an article Journal homepage
205
Views
26
CrossRef citations to date
0
Altmetric
Reviews

Can we predict the effects of NF-κB inhibition in sepsis? Studies with parthenolide and ethyl pyruvate

Xuemei Li Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China
,
Junwu Su Surgical Department of Pediatric Cardiology, Anzhen Hospital, Capital Medical University, Beijing, China
,
Xizhong Cui Critical Care Medicine Department, National Institutes of Health, Building 10, Room 2C145, Bethesda, MD 20892, USA +1 301 496 9320; +1 301 402 1213; [email protected]
,
Yan Li Critical Care Medicine Department, National Institutes of Health, Building 10, Room 2C145, Bethesda, MD 20892, USA +1 301 496 9320; +1 301 402 1213; [email protected]
,
Amisha Barochia Critical Care Medicine Department, National Institutes of Health, Building 10, Room 2C145, Bethesda, MD 20892, USA +1 301 496 9320; +1 301 402 1213; [email protected]
&
Peter Q Eichacker Critical Care Medicine Department, National Institutes of Health, Building 10, Room 2C145, Bethesda, MD 20892, USA +1 301 496 9320; +1 301 402 1213; [email protected]
Pages 1047-1060 | Published online: 26 Jun 2009

Bibliography

  • Danai PA, Sinha S, Moss M, et al. Seasonal variation in the epidemiology of sepsis. Crit Care Med 2007;35:410-15
  • Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. Crit Care Med 2001;29:1303-10
  • Sriskandan S, Altmann DM. The immunology of sepsis. J Pathol 2008;214:211-23
  • Minneci PC, Deans KJ, Banks SM, et al. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on dose. Ann Intern Med 2004;141:47-56
  • Eichacker PQ, Parent C, Kalil A, et al. Risk and efficacy of anti-inflammatory agents: Retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002;166:1196-205
  • Eichacker PQ, Danner RL, Suffredini AF, et al. Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial. Crit Care Med 2005;33:2426-8
  • Minneci PC, Deans KJ, Cui X, et al. Antithrombotic therapies for sepsis: a need for more studies. Crit Care Med 2006;34:538-41
  • Verstak B, Hertzog P, Mansell A. Toll-like receptor signaling and the clinical benefits that lie within. Inflamm Res 2007;56:1-10
  • Abraham E. Alterations in cell signaling in sepsis. Clin Infect Dis 2005;41(Suppl 7):S459-64
  • Fan J, Ye RD, Malik AB. Transcriptional mechanisms of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2001;281:L1037-50
  • Liu SF, Malik AB. NF-κB activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 2006;290:L622-45
  • Uwe S. Anti-inflammatory interventions of NF-κB signaling: Potential applications and risks. Biochem Pharmacol 2008;75:1567-79
  • Li X, Cui X, Li Y, et al. Parthenolide has limited effects of nuclear factor- κB increases and worsens survival in lipopolysaccharide-challenged C57BL/6J mice. Cytokine 2006;33:299-308
  • Su J, Li X, Cui X, et al. Ethyl pyruvate decreased early NF-κB levels but worsened survival in LPS-challenged mice. Crit Care Med 2008;36:1059-67
  • Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-80
  • Beutler B, Hoebe K, Du X, et al. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J Leukoc Biol 2003;74:479-85
  • Faure E, Equils O, Sieling PA, et al. Bacterial LPS activates NF-κB through toll-like receptor 4 (TLR-4) cultured human dermal endothelial cells: Differential expression of TLR-4 and TRL-2 in endothelial cells. J Biol Chem 2000;275:11063-508
  • Paik Y, Scwabe RF, Bataller R, et al. Toll-like receptor 4 mediates inflammatory signaling by bacterial LPS in human hepatic stellate cells. Hepatology 2003;37:1043-55
  • Bhattacharyya S, Dudeja PK, Tobacman JK. LPS activates NF-κB by TLR4-Bc110-dependent and independent pathways in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 2008;295:G784-90
  • Calkins CM, Barsness K, Bensard DD, et al. TLR-4 signalling mediates pulmonary neutrophil sequstration in response to gram-positive bacterial endotoxin. J Surg Res 2002;104:124-30
  • Zhou X, Gao X, Fan J, et al. LPS activation of TLR-4 signals CD11b/CD18 expression in neutrophils. Am J Physiol Lung Cell Mol Physiol 2005;288:L655-62
  • Jeyaseelan S, Chu HW, Young SK, et al. Distinct roles of pattern recognition receptors CD14 and TLR4 in acute lung injury. Infect Immun 2005;73:1754-63
  • Paik YH, Lee KS, Lee HJ, et al. Hepatic stellate cells primed with cytokines upregulate inflammation in response to peptidoglycan or lipoteichoic acid. Lab Invest 2006;86:676-86
  • Cho ML, Ju JH, Kim HR, et al. TRL2 ligand mediates the upregulation of angiogenic factor, vascular endothelial growth factor and interleukin-8/CXCL8 in human rheumatoid synovial fibroblasts. Immun Lett 2007;108:121-8
  • Lin W, Luo SF, Lee CW, et al. Involvement of MAPKS and NF-κB in LPS-induced VCAM-1 expression in human tracheal smooth muscle cells. Cell Signal 2007;19:1258-67
  • Zhang H, Tasaka S, Shiraishi Y, et al. Role of soluble receptor for advanced glycation end products on endotoxin-induced lung injury. Am J Respir Crit Care Med 2008;178:356-62
  • Perkins ND. Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol 2007;8:49-62
  • Neumann M, Naumann M. Beyond IκBs: alternative regulation activity. FASEB 2007;21:2642-54
  • Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: A treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26
  • Sun SC. Deubiquitylation and regulation of the immune response. Nat Rev Immunol 2008;8:501-11
  • Ghosh S, Hayden MS. New regulators of NF-κB in inflammation. Nat Rev Immun 2008;8:837-48
  • Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002;109:S81-96
  • Li Q, Verma IM. NF-κB regulation in the immune system. Nat Rev Immun 2002;2:725-34
  • Hayden MS, West AP, Ghosh MS. NF-κB and the immune response. Oncogene 2006;25:6758-80
  • Rossi AG, Hallett JM, Sawatzky DA, et al. Modulation of granulocyte apoptosis can influence the resolution of inflammation. Biochem Soc Trans 2007;35:288-91
  • Han SJ, Ko HM, Choi JH, et al. Molecular mechanisms for lipopolysaccharide-induced biphasic activation of NF-κB. J Biol Chem 2002;277:44715-21
  • Lawrence T, Gilroy DW, Colville-Nash PR, et al. Possible new role of NF-κB in the resolution of inflammation. Nat Med 2001;7:1291-7
  • Blackwell TS, Yull FE, Chen CL, et al. Multiorgan nuclear factor-kappaB activation in a transgenic mouse model of systemic inflammation. Am J Respir Crit Care Med 2000;162:1095-1101
  • Christman JW, Lancaster LH, Blackwell TS. Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med 1998;24:1131-8
  • Liu SF, Ye X, Malik AB. Inhibition of NF-κB by pyrrolidine dithiocarbamate prevents in vivo expression of pro-inflammatory genes. Circulation 1999;100:1330-7
  • Liu SF, Ye X, Malik AB. Pyrrolidine dithiocarbamate prevents I-κB degradation and reduces microvascular injury induced by LPS in multiple organs. Mol Pharmacol 1999;55:658-67
  • Liu SF, Ye X, Malik AB. In vivo inhibition of NF-κB activation prevents inducible nitric oxide synthase expression and systemic hypotension in a rat model of septic shock. J Immunol 1997;159:3976-83
  • Lauzurica P, Martinez-Martinez S, Marazuela M, et al. Pyrrolidine dithiocarbamate protects mice from lethal shock induced by LPS and TNF-α. Eur J Immunol 1999;29:1890-900
  • Ye X, Ding J, Zhou X, et al. Divergent roles of endothelial NF-κB in multiple organ injury and bacterial clearance in mouse models of sepsis. J Exp Med 2008;205:1303-15
  • Lu CC, Lai HC, Hsieh SC, et al. Resveratrol ameliorates Serratia marcescens-induced acute pneumonia in rats. J Leuk Biol 2008;83:1028-37
  • Leiva M, Ruiz-Bravo A, Jimenez-Valera M. Effects of Telithromycin in in vitro and in vivo models of LPS-induced airway inflammation. Chest 2008;134:20-9
  • Cheng DS, Han W, Chen SM, et al. Airway epithelium controls lung inflammation and injury through the NF-κB pathway. J Immunol 2007;178:6504-13
  • Matsuda N, Hattori Y, Jesmin S, et al. NF-κB decoy oligodeoxynucleotides prevent acute lung injury in mice with cecal ligation and puncture-induced sepsis. Mol Pharmacol 2005;67:1018-25
  • Matsuda N, Hattori Y, Takahashi Y, et al. Theraaapeutic effect of in vivo transfection of transcription factor decoy to NF-κB on septic lung in mice. Am J Physiol Lung Cell Mol Physiol 2004;287:L1248-55
  • Yang CH, Tsai PS, Lee JJ, et al. NF-κB inhibitors stabilize the mRNA of high-affinity type-2 cationic amino acid transporter in LPS-stimulated rat liver. Acta Anaesthesiol Scand 2005;49:468-76
  • Ogushi I, Iimuro Y, Seki E, et al. NF-κB decoy oligodeoxynucleotides prevent endotoxin-induced fatal liver failure in a murine model. Hepatology 2003;38:335-44
  • Lee S, Kim W, Kang KP, et al. Agonist of peroxisome proliferators-activated receptor-γ, rosiglitazone, reduces renal injury and dysfunction in murine sepsis model. Nephrol Dial Transplant 2005;20:1057-65
  • Pocock J, Gomez-Guerrero C, Harendza S, et al. Differential activation of NF-κB, AP-1, and C/EBP in endotoxin-tolerant rats: mechanisms for in vivo regulation of glomerular RANTES/CCL5 expression. J Immunol 2003;170:6280-91
  • Mora AL, LaVoy J, McKean M, et al. Prevention of NF-κB activation in vivo by a cell-permeable NF-κB inhibitor peptide. Am J Physiol Lung Cell Mol Physiol 2005;289:L536-44
  • Matsumori A, Nunokawa Y, Yamaki A, et al. Suppression of cytokines and nitric oxide production, and protection against lethal endotoxemia and viral myocarditis by a new NK-κB inhibitor. Eur J Heart Fail 2004;6:137-44
  • Arnalich F, Garcia-Palomero E, Lopez J, et al. Predictive value of NF-κB activity and plasma cytokine levels in patients with sepsis. Infect Immun 2000;68:1942-5
  • Adib-Conquy M, Adrie C, Moine P, et al. NF-κB expression in mononuclear cells of patients with sepsis resembles that observed in LPS tolerance. Am J Respir Crit Care Med 2000;162:1877-83
  • Bohrer H, Qiu F, Zimmermann T, et al. Role of NF-κB in the mortality of sepsis. J Clin Invest 1997;100:972-985
  • Schwartz MD, Moore EE, Moore FA, et al. NF-κB is activated in alveolar macrophages from patients with the acute respiratory distress syndrome. Crit Care Med 1996;24:1285-92
  • Senftleben U, Li ZW, Baud V, et al. IKKβ is essential for protecting T cells from TNFα. Immunity 2001;14:217-30
  • Chen LW, Egan L, Li ZW, et al. The two faces of IKK and NF-κB inhibition: Prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 2003;9:575-81
  • Cobb JP, Natanson C, Hoffman WD, et al. N omega-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin. J Exp Med 1992;176:1175-82
  • Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004;32:21-30
  • Fink MP. NF-κB: is it a therapeutic target for the adjuvant treatment of sepsis ? Crit Care Med 2003;31:2400-2
  • Zingarelli B. Ethyl pyruvate: A simple solution ? Crit Care Med 2004;2004:1603-4
  • Bork PM, Schmitz ML, Kuhnt M, et al. Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-kappaB. FEBS Lett 1997;402:85-90
  • Kwok BH, Koh B, Ndubuisi MI, et al. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol 2001;8:759-66
  • Lyss G, Knorre A, Schmidt TJ, et al. The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-kappaB by directly targeting p65. J Biol Chem 1998;273:33508-16
  • Garcia-Pineres AJ, Lindenmeyer MT, Merfort I. Role of cystein residues of p65/NF-κB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivation potential. Life Sci 2004;75:841-56
  • Hehner SP, Hofmann TG, Droge W, et al. The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappaB by targeting the I kappaB kinase complex. J Immunol 1999;163(10):5617-23
  • Mazor RL, Menendez IY, Ryan MA, et al. Sesquiterpene lactones are potent inhibitors of interleukin 8 gene expression in cultured human respiratory epithelium. Cytokine 2000;12(3):239-45
  • Hehner SP, Heinrich M, Bork PM, et al. Sesquiterpene lactones specifically inhibit activation of NF-kappaB by preventing the degradation of I kappa B-alpha and I kappa B-beta. J Biol Chem 1998;273(3):1288-97
  • Sheehan M, Wong HR, Hake PW, et al. Parthenolide, an inhibitor of the nuclear factor-kappaB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents. Mol Pharmacol 2002;61(5):953-63
  • Sheehan M, Wong HR, Hake PW, et al. Protective effects of isohelenin, an inhibitor of nuclear factor kappaB, in endotoxic shock in rats. J Endotoxin Res 2002;8:99-107
  • Sheehan M, Wong HR, Hake PW, et al. Parthenolide improves systemic hemodynamics and decreases tissue leukosequestration in rats with polymicrobial sepsis. Crit Care Med 2003;31(9):2263-70
  • O'Donnell-Tormey J, Nathan CF, Lanks K, et al. Secretion of pyruvate: an antioxidant defense of mammalian cells. J Exp Med 1987;165:500-14
  • Salahudeen AK, Clark EC, Nath KA. Hydrogen peroxide-induced renal injury: A protective role for pyruvate in vitro and in vivo. J Clin Invest 1991;88:1886-93
  • Brand KA, Hermfisse U. Aerobic glycolysis by proliferating cells: A protective strategy against reactive species. FASEB J 1997;11:388-95
  • Borle AB, Stanko RT. Pyruvate reduces anoxic injury and free radical formation in perfused rat hepatocytes. Am J Physiol 1996;270:G535-40
  • Deboer LW, Bekx PA, Han L, et al. Pyruvate enhances recovery of rat hearts after ischemia and reperfusion by preventing free radical generation. Am J Physiol 1993;265:H1571-6
  • Sims CA, Wattanasirichaigoon S, Menconi MJ, et al. Ringer's ethyl-pyruvate solution ameliorates ischemia/reperfusion-induced intestinal mucosal injury in rats. Crit Care Med 2001;29:1513-8
  • Yang R, Gallo DJ, Baust JJ, et al. Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol 2002;283:G212-21
  • Tawadrous ZS, Delude RL, Fink MP. Resuscitation from hemorrhagic shock with Ringer's ethyl pyruvate solution improves survival and ameliorates intestinal mucosal hyperpermeability in rats. Shock 2002;17:473-7
  • Sappington PL, Han X, Yang R, et al. Ethyl pyruvate ameliorates intestinal epithelial barrier dysfunction in endotoxemic mice and immunostimulated Caco-2 enterocytic monolayers. J Pharmacol Exp Ther 2003;304:464-76
  • Yang R, Han X, Delude RL, et al. Ethyl pyruvate ameliorates alcohol-induced liver injury and inflammation in mice. J Lab Clin Med 2003;142:322-31
  • Yang R, Uchiyama T, Watkins SK, et al. Ethyl pyruvate reduces liver injury in a murine model of extrahepatic cholestasis. Shock 2004;22:369-75
  • Venkataraman R, Kellum JA, Song M, et al. Resuscitation with Ringer's ethyl pyruvate solution prolongs survival and modulates plasma cytokine and nitrite/nitrate concentrations in a rat model of lipopolysaccharide-induced shock. Shock 2002;18:507-12
  • Ulloa L, Ochani M, Yang H, et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 2002;99:12351-6
  • Yang R, Uchiyama T, Alber SM, et al. Ethyl pyruvate ameliorates distant organ injury in a murine model of necrotizing pancreatitis. Crit Care Med 2004;32:1453-9
  • Sappington PL, Cruz RJ, Harada T, et al. The ethyl pyruvate analogues, diethyl oxaloproprionate, 2-acetamidacrylate, and methyl-2-acetamidacrylate, exhibit anti-infloammatory properties in vivo and/or in vitro. Biochem Pharmacol 2005;70:1579-92
  • Han Y, Englert JA, Yang R, et al. Ethyl pyruvate inhibits NF-κB-dependent signaling by directly targeting p65. J Pharmacol Exp Ther 2005;312:1097-115
  • Ajami AM, Sims CA, Fink MP. Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion. US6846842; 2005
  • Fink MP, Ulloa L, Tracey KJ, et al. Method of using pyruvate or its derivatives for the treatment of cytokine-mediated inflammatory conditions. US6943190; 2005
  • Bennet-guerrero E, Swaminathan M, Grigore AM, et al. A phase II multicenter double-blind placebo-controlled study of ethyl pyruvate in high-risk patients undergoing cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2008 [Epub]
  • Kisseleva T, Song L, Vorontchikhina M, et al. NF-κB regulation of endothelial cell function during LPS-induced, toxemia and cancer. J Clin Invest 2006;116:2955-63
  • Gadjeva M, Tomczak MF, Zhang M, et al. A role of NF-κB subunits p50 and p65 in the inhibition of LPS-induced shock. J Immunol 2004;173:5786-93
  • Andersson A, Fenammar J, Frithiof R, et al. Haemodynamic and metabolic effects of resuscitation with Ringer's ethyl pyruvate in acute phase of porcine endotoxemic shock. Acta Anaesthesiol Scand 2006;50:1198-206
  • Leelahavanichkul A, Yasuda H, Doi K, et al. Methyl-2-acetamidoacrylate, an ethyl pyruvate analog, decreases sepsis-induced acute kidney injury in mice. Am J Physiol Renal Physiol 2008;295:F1825-35
  • Das UN. Pyruvate is an endogenous anti-inflammatory and anti-oxidant molecule. Med Sci Monit 2006;12:RA79-84
  • Hollenbach M, Hintersdorf A, Huse K, et al. Ethyl pyruvate and ethyl lactate down-regulate the production of pro-inflammatory cytokines and modulate expression of immune receptors. Biochem Pharmacol 2008;76:631-44
  • Kim HS, Cho IH, Kim JE, et al. Ethyl pyruvate has an anti-inflammatory effect by inhibiting ROS-dependent STAT signaling in activated microglia. Free Radic Biol Med 2008;45:950-63
  • Wesche-Soldato DE, Swan RZ, Chung CS, et al. The apoptotic pathway as a therapeutic target in sepsis. Curr Drug Targets 2007;8:493-500
  • Brahmamdam P, Watanabe E, Unsinger J, et al. Targeted delivery of siRNA to cell death proteins in sepsis. Shock 2008
  • Gilmore TD, Herscovitch M. Inhibitors of NF-κB signaling: 785 and counting. Oncogene 2006;25:6887-99
  • Bernard GR, Vincent JL, Laterre PF, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
  • Abraham E, Laterre F, Garg R, et al. Drotrecogin Alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332-41
  • Lilly Plans New Clinical Trial, February 2007. Available from: http://wwww/newsroom.lilly/ReleaseDetail.cfm?ReleaseID = 231184 21k. [Accessed 11 December 2007]
  • Mack GS. Ariad pharmaceuticals wins first round over Eli Lilly, Patents on methods can be far-reaching. J Natl Cancer Inst 2006;98:1028-30
  • Joyce DE, Grinnel BW. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating NF-κB. Crit Care Med 2002;30:S288-93
  • Eichacker PQ, Natanson C. Increasing evidence that the risks of rhAPC may outweigh its benefits. Intensive Care Med 2007;33:396-9
  • Poli-de-Figueiredo LF, Garrido AG, Nakagawa N, et al. Experimental models of sepsis and their clinical relevance. Shock 2008;30(Suppl 1):53-9
  • Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: Setting the stage. Nat Rev Drug Discov 2005;4:854-65
  • Haley M, Parent C, Cui X, et al. Neutrophil inhibition with L-selectin-directed MAb improves or worsens survival dependent on the route but not severity of infection in a rat sepsis model. J Appl Physiol 2005;98:2155-62
  • Solomon SB, Cui X, Gerstenberger E, et al. Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of E. coli infection. J Infect Dis 2006;193:634-44
  • Karzai W, Cui X, Mehlborn B, et al. Protection with antibody to tumor necrosis factor differs with similarly lethal E. Coli nd S. aureus pneumonia in rats. Anesthesiology 2003;99:81-9
  • Karzai W, von Specht BU, Parent C, et al. G-CSF during E. coli versus S. aureus pneumonia in rats has fundamentally different and opposite effects. Am J Respir Crit Care Med 1999;159:1377-82

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.